ClinicalTrials.gg
RecruitingNCT05974488Updated Oct 6, 2025

The Efficacy of Distal Pharyngeal Airway for Oxygenation During TEE

An interventional study of McMurray Enhanced Airway and Nasal Cannula in Airway Obstruction, sponsored by University of Miami. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-06.

Sponsored by University of Miami · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Airway Obstruction with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Airway Obstruction · United States.

Planned enrollment
13th of 29
50 · median 41
Started
2023
with 4 others
No phase
23 of 40
4 open now
Registered
32nd of 40
by date

Among the 40 studies in Airway Obstruction with a site in United States, this one is the 13th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2023, is one of 23 with no phase, and was the 32nd registered.

Airway Obstruction

148 studies on the registry are indexed under Airway Obstruction; 26 are open to participants now.

Browse Airway Obstruction studies →

Open to participants now

8 of the 40 studies in Airway Obstruction with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Airway Obstruction studies recruiting now, 13 (65%) set no upper age limit and 5 (25%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Airway Obstruction with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of using the McMurray Enhanced Airway (MEA) which is a flexible extended-length distal pharyngeal airway on improving oxygen delivery compared to standard nasal cannula.

03

Conditions studied

  • Airway Obstruction

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > or = 18 years old
  • Patients willing to participate and provide an
  • Patients scheduled to undergo an elective TEE procedure.

Exclusion criteria

Exclusion Criteria:

  • Patients with history of uncontrolled gastroesophageal reflux disease
  • Patients with anatomical airway obstruction
  • Have any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Distal Pharyngeal Airway

    Participants in this group will use the McMurray enhanced airway to have oxygen delivered throughout a TEE procedure for up to 60 minutes.

    Device: McMurray Enhanced Airway

  • Active comparator
    Nasal cannula group

    Participant in this group will receive oxygen through a nasal cannula during the TEE procedure for up to 60 minutes.

    Device: Nasal Cannula

Interventions

  • DeviceMcMurray Enhanced Airway

    The MEA is non-sterile. It can be used in inpatient or outpatient surgery, in hospital or clinic settings, or in an emergency setting. The MEA has five parts: an optional 15 mm connector, flange (color-coded for size), elongated cushioned bite block, flexible cannula, and distal tip, and a channel to allow for passage of air and a suction catheter. The MEA is designed to open and maintain a patient's upper airway. Oxygen will be delivered through the breathing circuit with the following parameters: 40% oxygen at 6 liters/min flow throughout the procedure time. The MEA will be placed in the participant's oropharyngeal airway one time during an in-person visit.

  • DeviceNasal Cannula

    Participants in this group will use the nasal cannula to deliver oxygen as per standard of care one time during the in-person visit.

06

What researchers measure

Primary outcomes

  1. Incidence of hypoxia

    Determine the incidence of hypoxia defined as oxygen saturation by pulse oximetry (SPo2)= 75-89%.

    Time frame: during procedure (up to 60 minutes)

Secondary outcomes

  1. Incidence of subclinical hypoxia

    Determine the incidence of subclinical hypoxia defined as SPo2= 90-95%.

    Time frame: during procedure (up to 60 minutes)

  2. Incidence of severe Hypoxia

    Determine the incidence of severe hypoxia defined as SPo2\<75%.

    Time frame: during procedure (up to 60 minutes)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Oct 2026, 34 months after the start.

Of 36 non-industry interventional studies with no phase under Airway Obstruction, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 37. This study's planned 34 months is above that.

Counting every sponsor, half of 44 studies reached it within 16 months; a quarter within 3 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Aug 3, 2023
StartActual
Nov 30, 2023
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Oct 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05974488
Responsible party
Fouad souki (Associate Professor, University of Miami) — Principal investigator
First posted
Aug 3, 2023
Start date
Nov 30, 2023
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Oct 6, 2025

Study contacts

Fouad G Souki, MD
Contact
fsouki@med.miami.edu
(305) 5857435
Fouad G Souki, MD
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion